Shuttle Pharmaceuticals submits IND application to U.S. FDA for Ropidoxuridine

Shuttle Pharmaceuticals announced submission of an Investigational New Drug, IND, application with the U.S. Food and Drug Administration, FDA, to support the next phase of development of Ropidoxuridine. Ropidoxuridine is Shuttle Pharma’s lead radiation sensitizer candidate for use in combination with radiation therapy to treat brain tumors, a deadly malignancy of the brain with no known cure. “Today’s announcement is an important milestone for Shuttle Pharma and the thousands of patients with brain tumors who currently lack effective therapies,” stated Shuttle Pharma’s Chairman and CEO, Anatoly Dritschilo, M.D. “The IND submission is the culmination of many years of clinical development by the Shuttle Pharma team, as well as support from the broader cancer community, including the National Institutes of Health’s National Cancer Institute and Small Business Innovation Research program, who have provided guidance and grant funding to bring this potentially important new radiation sensitizing therapy to market.”